

DAFTAR PUSTAKA

1. Inker L, Astor B, Fox C. KDIGO 2012 Clinical practice guideline for the evaluation and management of CKD. *Kidney Inter Suppl.* 2013; 3:1-150.
2. Levey AS, Coresh J. Chronic kidney disease. *Lancet.* 2012; 379(9811):165-80.
3. Thomas B, Wulf S, Bikbov B, Perico N, Cortinovis M, Courville K. Maintenance dialysis throughout the world in years 1990 and 2010. *J Am Soc Nephrol.* 2015; 26: 2621–2633.
4. U.S. Renal Data System (USRDS): USRDS 2013 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, Bethesda, MD, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2013.
5. PERNEFRI. 10th Report of Indonesian Renal Registry. Perhimpunan Nefrolog Indonesia. 2017.
6. Badan penelitian dan pengembangan Kesehatan. Riset Kesehatan Dasar (RISKESDAS). Jakarta: Kemenkes RI; 2013.
7. Cheung WW, Paik KH, Mak RH. Inflammation and cachexia in chronic kidney disease. *Pediatr Nephrol* 2010; 25:711-24.
8. Amedeo F, Vecchi D, Bamonti F, Novembrino C, Ippolito S, Guerra L, et al. Free and total plasma malondialdehyde in chronic renal insufficiency and in dialysis patients. *Nephrol Dial Transplant.* 2009; 24:2524–2529.
9. Cheng J and Grande J. Transforming growth factor-beta signal transduction and progressive renal disease. *Exp Biol Med (Maywood).* 2020; 227: 943–956.

10. Czopek A, Moorhouse R, Webb D, Dhaun N. Therapeutic potential of endothelin receptor antagonism in kidney disease. *Am J Physiol Regul Integr Comp Physiol*. 2016; 310:R388-R397.
11. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. *Nature*. 1988; 332:411–415.
12. Dhaun N, Goddard J, Webb D. The endothelin system and its antagonism in chronic kidney disease. *J Am Soc Nephrol*. 2006; 17:943–955.
13. Kohan E, Inscho E, Wesson D, Pollock D. Physiology of endothelin and the kidney. *Compr Physiol*. 2011; 1(2):883-919.
14. Barton M, Sorokin A. Endothelin and glomerulus in chronic kidney disease. *Semin Nephrol*. 2015; 35(2):156-67.
15. Zager R, Johnson A, Andress D. Progressive endothelin-1 gene activation initiates chronic end-stage renal disease following experimental ischemic/reperfusion injury. *Kidney Int*. 2013; 84:703-12.
16. Gansevoort R, Matsushita K, van der Velde M. Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes. A collaborative meta-analysis of general and high-risk population cohorts. *Kidney Int*. 2011; 80:93–104.
17. Hemmelgarn B, Manns B, Lloyd A. Relation between kidney function, proteinuria, and adverse outcomes. *JAMA*. 2010; 303:423–429.
18. Liu J, Robbins D, Palmieri V. Association of albuminuria with systolic and diastolic left ventricular dysfunction in type 2 diabetes: the Strong Heart Study. *J Am Coll Cardiol*. 2003; 41:2022–2028.
19. Viswanathan G, Upadhyay A. Assessment of proteinuria. *Adv Chronic Kidney Dis*. 2011; 18:243–248.
20. Pavenstadt H, Kriz W, Kretzler M. Cell biology of the glomerular podocyte. *Physiol Rev*. 2003; 83(1):253–307.

21. Raij L, Tian R, Wong J, He J, Campbell K. Podocyte injury: the role of proteinuria, urinary plasminogen, and oxidative stress. *Am J Physiol Renal Physiol.* 2016; 311:F1308-F1317.
22. Li F, Hagaman J, Kim H, Maeda N, Jennette C, Faber E, et al. eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. *J Am Soc Nephrol.* 2012; 23:652–60.
23. Saleh A, Boesen I, Pollock S, Savin J, Pollock M. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. *Hypertension.* 2010; 56:942–9.
24. Nagase M, Shibata S, Yoshida S, Nagase T, Gotoda T, Fujita T. Podocyte injury underlies the glomerulopathy of dahl salt-hypertensive rats and is reversed by aldosterone blocker. *Hypertension.* 2006; 47:1084-1093.
25. Garsen M, Lenoir O, Rops A, Dijkman H, Willemsem B, Kuppevelt T, et al. Endothelin-1 induces proteinuria by heparanase-mediated disruption of the glomerular glycocalyx. *J Am Soc Nephrol.* 2016; 27:3545-3551.
26. Boels M, Avramut M, Koudijs A, Dane M, Lee D, Van D. Atrasentan reduces albuminuria by restoring the glomerular endothelial glycocalyx barrier in diabetic nephropathy. *Diabetes.* 2016; 65:2429-2439.
27. Zeravica R, Ilincic B, Cabarkapa V, Sakac V, Crnobrnja V, Stosic Z. Plasma endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. *Medicinski preglod.* 2016; 69:140-145.
28. Zanatta M, Gerchman F, Burtet L, Nabinger G, Jacques C, Canani H, et al. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. *Diabetes Res Clin Pract.* 2008; 80:299-303.
29. Zhang Q, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. *BMC Public Health.* 2008; 8:117.
30. Alani H, Tamimi A. Cardiovascular comorbidity in chronic kidney disease: Current knowledge and future research needs. *World J Nephrol.* 2014; 156-

68.

31. Levey A, Inker L, Matsushita K. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. *AM J Kidney Dis.* 2014; 64(6):821-835
32. Earley A, Miskulin D, Lamb E, Levey A, Uhlig K. Estimating equations for glomerular filtration rate in the era of creatinine standardization: a systematic review. *Ann Intern Med.* 2012; 156(11):785-795.
33. Wang H, Naghavi M, Allen C. GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. *Lancet* 2016; 388:1459–544.
34. Sherwood, Lauralee. Sistem Kemih. Fisiologi Manusia dari Sel ke Sistem. Edisi 2. Jakarta : Penerbit Buku Kedokteran ECG ; 2001.463 – 503.
35. Krane V, Wanner C. Statins. Inflammation and kidney disease. *Nat Rev Nephrol.* 2011; 7:385-97.
36. Kohan E, Inscho E, Wesson D , Pollock D. Physiology of endothelin and the kidney. *Compr Physiol.* 2011; 1(2):883-919.
37. Kohan E. Role of collecting duct endothelin in control of renal function and blood pressure. *Am J Physiol Regul Integr Comp Physiol.* 2013; 305(7):R659-68.
38. Lukas E, Spieker M, Georg N, Frank T, Ruschitzka M, Thomas F, et al. Endothelin receptor antagonists in congestive heart failure: A new therapeutic principle for the future?. *Journal of the American College of Cardiology.* 2001; 32: 35-37.

39. Wendel M, Knels L, Kummer W, Koch T. Distribution of endothelin receptor subtypes ETA and ETB in the rat kidney. *J Histochem Cytochem.* 2006; 5:1193–1203.
40. Schildroth J, Rettig Z, Kalk P, Steege A, Fahling M, Sendeski M, et al. Endothelin type A and B receptors in the control of afferent and efferent arterioles in mice. *Nephrol Dial Transplant.* 2011; 2:779–789.
41. Anguiano L, Pascual J, Soler M. Endothelin Blockade in Diabetic Kidney Disease. *J Clin Med.* 2015; 4:1171-92.
42. Jefferson J, Shankland S, Pichler R. Proteinuria in diabetic kidney disease: A mechanistic viewpoint. *Kidney International.* 2008; 74:22-36.
43. Solomon S, Lin J, Jablonski K, Rice M, Steffes M, Domanski M, et al. Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease. *Circulation.* 2007; 116:2687–2693.
44. Warnock D, Muntner P, McCullough P, Zhang X, McClure L, Zakai N, et al. Kidney function, albuminuria, and all-cause mortality in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) study. *Am J Kidney Dis.* 2010; 56:861–871.
45. Matsushita K, Astor B, Woodward M, Levey A, de Jong P, Coresh J, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet.* 2010; 375:2073–2081.
46. Fligny C, Barton M, Tharaux P. Endothelin and podocyte injury in chronic kidney disease. *Contrib Nephrol.* 2011; 172:120–138.
47. Maguire J, Davenport A. Endothelin receptors and their antagonist. *Semin Nephrol.* 2015; 35:125-136
48. Petermann A, Floege J. Podocyte damage resulting in podocyturia: a potential diagnostic marker to assess glomerular disease activity. *Nephron Clin Pract.* 2007; 106:c61–66.
49. Welsh G, Saleem M. The podocyte cytoskeleton-key to a functioning glomerulus in health and disease. *Nat Rev Nephrol.* 2012; 8:14–21,44.

50. Shankland S, Pippin J, Reiser J. Podocytes in culture: past, present, and future. *Kidney Int.* 2007; 72:26–36 45.
51. Endlich N, Kress K, Reiser J. Podocytes respond to mechanical stress in vitro. *J Am Soc Nephrol.* 2001; 12:413–422.
52. Shankland S. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. *Kidney Int.* 2006; 69:2131–2147
53. Matsusaka T, Sandgren E, Shintani A. Podocyte injury damages other podocytes. *J Am Soc Nephrol.* 2011; 22:1275–1285.
54. Barton M, Yanagisawa M. Endothelin : 20 Years from Discovery to Therapy. *J Physiol.* 2008; 86:485-498.
55. Trakada G, Spiropoulos K, Nikolaou E, Prodromakis E, Efremidis G, Pouli A, et al. Endothelin-1 levels in the pathophysiology of chornic pulmonary disease and bronchial astma. *Respir Med.* 2011; 97(8):983-9
56. Dhaun N, Macintyre I, Melville V. Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease. *Hypertension.* 2009; 54:e19–20 .
57. Wenzel R, Littke T, Kuranoff S. Avosentan reduces albumin excretion in diabetics with mUACRoalbuminuria. *J Am Soc Nephrol.* 2009; 20:655–64.
58. Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, et al. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. *Am J Physiol Renal Physiol.* 2009; 297: F1448–F1456.
59. Watson A, Li J, Schumacher C, de Gasparo M, Feng B, Thomas M, et al. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. *Diabetologia* 2010; 53:192–203.
60. Kohan D, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, et al. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. *J Am Soc Nephrol.* 2011; 22: 63–772.

61. De Zeeuw D, Coll B, Andress D, Brennan J, Tang H, Houser M, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy. *J Am Soc Nephrol*. 2014; 25:1083–1093.
62. Dimitrov B, Perna A, Ruggenti P, Remuzzi G. Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. *Kidney Int*. 2003; 63:1924–1933.
63. Lemley K, Blouch K, Abdullah I, Boothroyd D, Bennett P, Myers B, et al. Glomerular permselectivity at the onset of nephropathy in type 2 diabetes mellitus. *J Am Soc Nephrol*. 2000; 11:2095–2105.
64. Andersen S, Blouch K, Bialek J, Deckert M, Parving H, Myers B. Glomerular permselectivity in early stages of overt diabetic nephropathy. *Kidney Int*. 2000; 58:2129–2137.
65. Witte E, Lambers H, De Zeeuw D. First morning voids are more reliable than spot urine samples to assess microalbuminuria. *J Am Soc Nephrol*. 2009; 20: 436-443.
66. Gosling J, Czyz P, Nightingale M, Manji. Microalbuminuria in the intensive care unit: clinical correlates and association with outcomes in 431 patients. *Crit Care Med*. 2006; 34:2158-2166.
67. Goddard J, Turner A, Stewart L, Colledge N, Walker B, Ralston S. Kidney and urinary tract disease. *Davidson's Principle and Practice of Medicine*. 21st International ed. Churchill Livingstone Elsevier. 2010:480-496.
68. Dwyer B, Gorman M, Carroll I, Druzin M. Urinalysis vs urine protein-creatinine ratio to predict significant proteinuria in pregnancy. *J Perinatol*. 2008; 28(7):461–7
69. National Kidney Foundation. K/DOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease. *Am J Kidney Dis*. 2007; 49(2 suppl 2):S1-180.
70. Molitch M, DeFronzo R, Franz M, Keane W, Mogensen C, Parving H, et al. Nephropathy in Diabetes.(American Diabetes Association Position Statement). *Diabetes Care*. 2004;27:79-83.

71. International Diabetes Federation, 2012 Clinical Guidelines Task Force Global Guideline for Type 2 Diabetes.
72. Burden R, Tomson C. Guideline Development Committee, Joint Specialty Committee on Renal Disease of the Royal College of Physicians of London and the Renal Association: identification, management and referral of adults with chronic kidney disease: concise guidelines. *Clin Med* 2005;5:635–642.
73. Bruno C, Meli S, Marcinno M, Ierna D, Sciacca C, Neri S. Plasma endothelin-1 levels and albumin excretion rate in normotensive, microalbuminuric type 2 diabetic patients. *J Biol Regul Homeost Agents*. 2002; 16:114-17.
74. Soelistijo S. *Konsensus pengelolaan dan pencegahan diabetes mellitus di Indonesia* Jakarta: PB PERKENI; 2015.
75. Anand S, Shivashankar R, Ali MK, Kondal D, Binukumar B, Montez M, et al. Prevalence of chronic kidney disease in two major Indian cities and projection for associated cardiovascular disease. *Kidney Int*. 2015; 88 (1) : 178-185
76. Dubey A, Sahoo J, Vairappan B, Haridasan S, Parameswaran S, Priyamvada P. Correction of metabolic acidosis improve muscle mass and renal fuction in CKD stage 3 and 4: A Randomized control trial. *Nephrol Dial Transplant*. 2018; 1-9.
77. Trivedi H, Vanikar A, Patel H, Kanodia K, Kute V, Nigam L, et al. High prevalence of chronic kidney disease in a-semi urban population of Western India. *Clin Kidney*. 2016; 9(3) :438-43
78. Hasan M, Sutradhar I, Das Gupta1 R, Sarker M. Prevalence of chronic kidney disease in South Asia: a systematic review. I. *BMC Nephrology*. 2018 ;19:291
79. Habib K, Mallhi K, Sarriff A, Khan A, Tanveer N. Prevalence of chronic kidney disease in Asia: A systematic review of population-based studies. *Journal of the College of Physicians and Surgeons Pakistan* 2018 ;12: 960-966
80. Singh A, Farag Y, Mittal B, Subramanian K, Reddy S, Acharya V, et al. Epidemiology and risk factors of chronic kidney disease in India-results from the SEEK (screening and early evaluation of kidney disease) study. *BMC Nephrol* 2013; 14:114

81. Imran S, Shiekh A, Saeed Z, Khan SA, Malik AO, Patel J. Burden of chronic kidney disease in an urban city of Pakistan, a cross-sectional study. *J Pak Med Assoc* 2015; 65:366-9
82. Neugarten J, Golestaneh L. Gender and the prevalence and progression of renal disease. *Adv Chronic Kidney D.* 2013;20(5):390-5.
83. Silbiger S, Neugarten J. Gender and human chronic renal disease. *Gend Med.* 2008;5:S3-S10.
84. Goldberg I, Krause I. The role of gender in chronic kidney disease. *EMJ.* 2016;1[2]:58-64.
85. Seki M , Nakayama, Sakoh T, Yoshitomi R , Fukui A , Katafuchi E, et al. Blood urea nitrogen is independently associated with renal outcomes in Japanese patients with stage 3–5 chronic kidney disease: a prospective observational study. *BMC Nephrology.*2019; 20:115
86. Moranne O, Froissart M, Rosset J, Gauci C, Boffa J. The Nephrotest Study Group: Timing of onset of CKD-related metabolic complications. *J Am Soc Nephrol.* 2009; 20(1):164-171.
87. Hsuan Y, Huey W, Jane L, Sing W, Chia P, Liang K. Synergistic effect of renalase and chronic kidney disease on endothelin-1 in patients with coronary artery disease- cross- sectional study. *Scientific Reports.*2018; 8:7378
88. Zoccali C, Leonardis D, Parlongo S, Mallamaci F, Postorino M. Endothelin 1 in essential hypertension and in hypertension secondary to renoparenchymal disease. *Nephrol Dial Transplant,* 1995; 10(8):1320-1322
89. Ruschitzka, F. et al. Endothelial dysfunction in acute renal failure: role of circulating and tissue endothelin-1. *J Am Soc Nephrol.* 1999;10:953–962
90. Tai M, Lam K, Lee W, Hsu K, Wu C, Cheng B, et al. Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease. *Journal of Clinical Laboratory Analysis.* 2012;26: 82–9
91. Ernesto L, Schiffrin, Mark L, Lipman, Johannes. Chronic kidney disease. Effect on the cardiovascular system. *AHA Journals.* 2007;116: 85-97
92. Mafham M, Staplin N, Emberson J, Haynes R , Herrington W , Reith C, et al. Prognostic utility of estimated albumin excretion rate in chronic kidney

disease: results from the Study of Heart and Renal Protection. *Nephrol Dial Transplant*. 2018; 33: 257–264

93. Raina R, Lou L, Berger B, Vogt B, Sao-MaiDo A, Cunningham R, et al. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis. *BMC Nephrology*. 2016; 22:88-98
94. Drakopoulos A, Dimitrios S, Goumenos, Vlachojannis J. Endothelin receptors in the kidney of patients with proteinuric and non-proteinuric nephropathies. *Renal Failure*. 2006;28:461-467
95. Zhou Y, Qi C, Li S, Shao X, Mou S, Ni Z. Diabetic nephropathy can be treated with calcium dobesilate by alleviating the chronic inflammatory state and improving endothelial cell function. *Cellular Physiology and Biochemistry*. 2018. 51:1119-1133

